[{"from": "human", "value": "Describe this molecule. [C][=C][C][=Branch1][#Branch2][=C][Branch1][=Branch1][C][=C][Ring1][=Branch1][I][F][N][C][=C][Branch1][O][C][=C][C][=Branch1][Branch1][=C][Ring1][=Branch1][F][F][C][=Branch1][C][=O][N][O][C][C@@H1][Branch1][Ring1][C][O][O]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors."}]